New cream offers hope for stubborn skin disease

NCT ID NCT06857240

Summary

This study is testing whether a topical cream called ruxolitinib is safe and effective for treating severe skin symptoms in adults with dermatomyositis, an autoimmune disease. The cream is being studied in 15 participants whose skin symptoms have not improved with other standard treatments. The goal is to see if applying this cream to affected skin areas can reduce inflammation and improve skin health without the side effects of long-term steroid creams.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact

Conditions

Explore the condition pages connected to this study.